Compare · DRMA vs NVO
DRMA vs NVO
Side-by-side comparison of Dermata Therapeutics Inc. (DRMA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRMA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $187.53B, about 36712.1x DRMA ($5.1M).
- Over the past year, DRMA is down 81.4% and NVO is down 41.7% - NVO leads by 39.7 points.
- NVO has been more active in the news (11 items in the past 4 weeks vs 8 for DRMA).
- NVO has more recent analyst coverage (25 ratings vs 2 for DRMA).
- Company
- Dermata Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $1.26-8.00%
- $42.01-2.10%
- Market cap
- $5.1M
- $187.53B
- 1M return
- -5.60%
- -5.38%
- 1Y return
- -81.42%
- -41.69%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 8
- 11
- Recent ratings
- 2
- 25
Dermata Therapeutics Inc.
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DRMA
- SEC Form EFFECT filed by Dermata Therapeutics Inc.
- SEC Form 424B3 filed by Dermata Therapeutics Inc.
- Dermata Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Amendment: SEC Form S-3/A filed by Dermata Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Dermata Therapeutics Inc.
- SEC Form 10-Q filed by Dermata Therapeutics Inc.
- Dermata Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Dermata Therapeutics Inc.
- SEC Form DEFA14A filed by Dermata Therapeutics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates